Novartis completes $12 billion acquisition of Avidity Biosciences
The deal was executed via a merger of Novartis’ wholly owned subsidiary, Ajax Acquisition Sub, Inc., into Avidity
The deal was executed via a merger of Novartis’ wholly owned subsidiary, Ajax Acquisition Sub, Inc., into Avidity
The product addresses a market with approximately $66.8 million in annual sales as of December 2025.
Vinita has made expansion in the U.S. a core pillar of Lupin’s worldwide growth strategy
Lupin attained a score of 91 out of 100, establishing itself as the leading pharmaceutical company globally
KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients
The TacroType test provides actionable genetic insights to help clinicians understand how individual patients metabolize tacrolimus
The results, published in The Lancet, showed orforglipron delivered significantly greater reductions in both A1C and body weight across primary and key secondary endpoints
PEACE-3 is a strong example of how academic cooperative research can help advance progress for complex diseases such as metastatic prostate cancer
The initiative, funded entirely under the company’s CSR programme, is expected to reach over a million lives
Subscribe To Our Newsletter & Stay Updated